
|Videos|July 11, 2017
Phase III Findings for Lenvatinib in HCC
Author(s)Ann-Lii Cheng, MD
Ann-Lii Cheng, MD, discusses a phase III trial of lenvatinib vs sorafenib in the first-line treatment of patients with unresectable hepatocellular carcinoma.
Ann-Lii Cheng, MD, discusses a phase III trial of lenvatinib vs sorafenib in the first-line treatment of patients with unresectable hepatocellular carcinoma.